Published in Neoplasia on April 01, 2006
The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr (2012) 1.46
Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway. PLoS One (2011) 0.95
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br J Haematol (2012) 0.85
Halofuginone enhances the radiation sensitivity of human tumor cell lines. Cancer Lett (2009) 0.83
Local inhibition of angiogenesis by halofuginone coated silicone materials. J Mater Sci Mater Med (2012) 0.80
A red wine polyphenolic extract reduces the activation phenotype of cultured human liver myofibroblasts. World J Gastroenterol (2008) 0.78
Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model. J Exp Clin Cancer Res (2015) 0.78
Neoplasia: the second decade. Neoplasia (2008) 0.75
Halofuginone suppresses growth of human uterine leiomyoma cells in a mouse xenograft model. Hum Reprod (2016) 0.75
Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract. World J Gastroenterol (2014) 0.75
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Primary liver cancer: worldwide incidence and trends. Gastroenterology (2004) 11.21
Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res (1998) 4.39
Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49
A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology (2005) 3.26
The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem (1998) 2.71
Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis (1999) 1.70
Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology (2001) 1.68
TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem (1998) 1.59
Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res (2000) 1.53
Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res (2005) 1.36
Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant (2003) 1.23
Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J (2000) 1.18
Growth inhibition of prostate cancer xenografts by halofuginone. Prostate (2002) 1.07
Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J Hepatol (1997) 1.07
Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology (2001) 1.05
Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med (1996) 1.00
Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur J Cancer (2004) 0.97
Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model--an MRI study. Neoplasia (2004) 0.95
Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res (1999) 0.94
In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis. J Hepatol (1997) 0.93
Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin Cancer Res (1999) 0.92
Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Poult Sci (1991) 0.91
Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. J Invest Dermatol (1996) 0.90
Effects of bile acids on biliary epithelial cell proliferation and portal fibroblast activation using rat liver slices. Lab Invest (2006) 0.89
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res (2003) 0.86
Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. J Urol (2005) 0.85
Establishment of an in vivo highly metastatic rat hepatocellular carcinoma model. Jpn J Cancer Res (1999) 0.80
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology (2007) 3.18
Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet (2002) 2.85
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J (2010) 2.73
Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res (2003) 2.37
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol (2012) 2.26
In vivo MR imaging of intravascularly injected magnetically labeled mesenchymal stem cells in rat kidney and liver. Radiology (2004) 2.22
Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology (2009) 2.20
Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol (2008) 2.16
A six-gene signature predicting breast cancer lung metastasis. Cancer Res (2008) 2.09
Inhibitory signalling to the Arp2/3 complex steers cell migration. Nature (2013) 2.06
The IIIc alternative of Fgfr2 is a positive regulator of bone formation. Development (2002) 2.04
Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer. Breast Cancer Res Treat (2012) 1.97
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol (2011) 1.97
Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res (2003) 1.84
Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone. Am J Physiol Heart Circ Physiol (2008) 1.79
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer (2008) 1.72
In vivo silencing of Reptin blocks the progression of human hepatocellular carcinoma in xenografts and is associated with replicative senescence. J Hepatol (2010) 1.71
Sphincter-saving resection for all rectal carcinomas: the end of the 2-cm distal rule. Ann Surg (2005) 1.65
Real-time MR temperature mapping of rabbit liver in vivo during thermal ablation. Magn Reson Med (2003) 1.62
Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology (2005) 1.54
Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology (2005) 1.52
Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology (2005) 1.52
Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology (2005) 1.48
Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene (2004) 1.48
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Res (2012) 1.47
NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat (2010) 1.47
In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. J Pathol (2010) 1.41
Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet (2011) 1.38
Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Crit Care Med (2006) 1.37
Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol (2006) 1.36
Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci (2003) 1.29
Osteopontin expression in normal and fibrotic liver. altered liver healing in osteopontin-deficient mice. J Hepatol (2005) 1.29
SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol (2014) 1.27
Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology (2004) 1.26
CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer (2010) 1.26
Cellular retinol-binding protein-1 expression and modulation during in vivo and in vitro myofibroblastic differentiation of rat hepatic stellate cells and portal fibroblasts. Lab Invest (2002) 1.23
Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum Mol Genet (2009) 1.21
Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. Mol Cancer (2004) 1.19
The multifaceted proteins Reptin and Pontin as major players in cancer. Biochim Biophys Acta (2010) 1.19
Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res (2003) 1.19
Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol (2007) 1.18
Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis. J Am Coll Surg (2004) 1.17
NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience. Hum Mutat (2013) 1.17
Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int (2008) 1.17
International study group on rectal cancer regression grading: interobserver variability with commonly used regression grading systems. Hum Pathol (2012) 1.16
Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1. J Natl Cancer Inst (2011) 1.16
ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. Cancer Res (2012) 1.16
Low rectal cancer: classification and standardization of surgery. Dis Colon Rectum (2013) 1.16
Pontin and reptin, two related ATPases with multiple roles in cancer. Cancer Res (2008) 1.15
Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuromuscul Disord (2008) 1.15
Perineal transanal approach: a new standard for laparoscopic sphincter-saving resection in low rectal cancer, a randomized trial. Ann Surg (2014) 1.14
Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C. Proteomics (2005) 1.14
Th17 cells and IL-17 in protective immunity to vaginal candidiasis. PLoS One (2011) 1.12
The Wnt antagonist Dickkopf-1 increases endothelial progenitor cell angiogenic potential. Arterioscler Thromb Vasc Biol (2010) 1.11
Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. Arterioscler Thromb Vasc Biol (2010) 1.11
Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos (2009) 1.10
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene (2002) 1.10
Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology (2007) 1.08
Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis (2007) 1.08
Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis. J Natl Cancer Inst (2011) 1.07
Growth inhibition of prostate cancer xenografts by halofuginone. Prostate (2002) 1.07
Inhibition of rat liver fibrogenesis through noradrenergic antagonism. Hepatology (2002) 1.06
Fibrillin-1 expression in normal and fibrotic rat liver and in cultured hepatic fibroblastic cells: modulation by mechanical stress and role in cell adhesion. Lab Invest (2004) 1.05
PAR-1 activation on human late endothelial progenitor cells enhances angiogenesis in vitro with upregulation of the SDF-1/CXCR4 system. Arterioscler Thromb Vasc Biol (2005) 1.05
Prevention of liver cirrhosis in rats by curcumin. Liver Int (2007) 1.05
Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood (2010) 1.04
Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Hum Mol Genet (2005) 1.04
Fos but not Cart (cocaine and amphetamine regulated transcript) is overexpressed by several drugs of abuse: a comparative study using real-time quantitative polymerase chain reaction in rat brain. Neurosci Lett (2003) 1.04
A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression. Blood (2007) 1.04
Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances in vitro angiogenesis with up-regulation of integrin alpha(6). J Cell Mol Med (2007) 1.03
Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet (2012) 1.03
Human chorionic gonadotropin produced by the invasive trophoblast but not the villous trophoblast promotes cell invasion and is down-regulated by peroxisome proliferator-activated receptor-gamma. Endocrinology (2007) 1.03
Identification of genes potentially involved in the increased risk of malignancy in NF1-microdeleted patients. Mol Med (2010) 1.03
Placenta-specific INSL4 expression is mediated by a human endogenous retrovirus element. Biol Reprod (2002) 1.03
Cellular retinol-binding protein-1 expression in normal and fibrotic/cirrhotic human liver: different patterns of expression in hepatic stellate cells and (myo)fibroblast subpopulations. J Hepatol (2004) 1.03
Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol (2012) 1.02